Sanofi India Q3 Profit Jumps 54% to ₹117 Crore as Insulin Grows 9% and Public Sector Sales Surge 85%; ₹75 Interim Dividend
Sanofi India’s Q3 2026 profit rose 53.6% to ₹117 crore on revenue of ₹491.7 crore, as its insulin portfolio grew 9% and public sector sales jumped 85% on new analogue accounts. EBITDA margin widened to 32.8% and the board declared a ₹75 interim dividend.
